ATLANTA, GA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “we,” “us” or “our”) (NYSE American: RHE) (NYSE American: RHE-PA) announced today that the Company received a notice from the NYSE American LLC (the “Exchange”) on February 21, 2023 that the Company has regained compliance with the continued listing standard set forth in Section 704 of the NYSE American Company Guide. Specifically, the Company has resolved the continued listing deficiency with respect to its failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021.
In the notification, the Exchange informed the Company that the below compliance (“BC”) indicator ceased to be disseminated on February 22, 2023. The Company was removed from the list of issuers noncompliant with NYSE American corporate governance listing standards posted on https://www.nyse.com/regulation/noncompliant-issuers and the BC indicator was removed from the profile, data and news pages of the Company’s security.
About Regional Health Properties
Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.
Company Contact | Investor Relations |
Brent Morrison, CFA | Brett Maas |
Chief Executive Officer & President | Managing Partner |
Regional Health Properties, Inc. | Hayden IR |
Tel (678) 368-4402 | Tel (646) 536-7331 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$2.77 |
Daily Volume: | 0 |
Market Cap: | US$5.220M |
November 26, 2024 November 17, 2023 August 03, 2023 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load